iifl-logo

Arvind Remedies Ltd Share Price

4.65
(-4.12%)
Jun 13, 2016|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Arvind Remedies Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

4.7

Prev. Close

4.85

Turnover(Lac.)

0.08

Day's High

4.7

Day's Low

4.65

52 Week's High

0

52 Week's Low

0

Book Value

-27.45

Face Value

10

Mkt Cap (₹ Cr.)

31.68

P/E

0

EPS

0

Divi. Yield

0

Arvind Remedies Ltd Corporate Action

No Record Found

Arvind Remedies Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Arvind Remedies Ltd SHAREHOLDING SNAPSHOT

26 Apr, 2025|11:32 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 3.57%

Foreign: 0.00%

Indian: 3.57%

Non-Promoter- 0.02%

Institutions: 0.01%

Non-Institutions: 96.40%

Custodian: 0.00%

Share Price

Arvind Remedies Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Equity Capital

68.13

68.13

64.39

48.23

Preference Capital

0

0

0

0

Reserves

-110.41

211.34

129.87

94.86

Net Worth

-42.28

279.47

194.26

143.09

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Revenue

787.06

911.1

664.26

436.62

yoy growth (%)

-13.61

37.16

52.13

20.43

Raw materials

-790.06

-683.61

-497.08

-347.14

As % of sales

100.38

75.03

74.83

79.5

Employee costs

-15.98

-17.41

-13.44

-9.08

View Profit & Loss
Y/e 31 Mar( In .Cr)Jun-2015Mar-2014Mar-2013Mar-2012

Profit before tax

-137.82

86.39

62.55

37.21

Depreciation

-29.46

-13.9

-12.58

-3.23

Tax paid

5.23

-27.49

-21.93

-17.8

Working capital

-54.91

173.49

115.59

47.78

Other operating items

View Cash Flow
Y/e 31 MarJun-2015Mar-2014Mar-2013Mar-2012

Growth matrix (%)

Revenue growth

-13.61

37.16

52.13

20.43

Op profit growth

-124.38

32.3

97.29

64.34

EBIT growth

-140.82

34.3

87.47

65.81

Net profit growth

-643.37

45

109.25

14.83

View Ratios
Particulars (Rupees in Crores.)Mar-2014Mar-2013Mar-2012

Gross Sales

961.28

704.35

467.07

Excise Duty

0

0

0

Net Sales

961.28

704.35

467.07

Other Operating Income

1.39

1.75

0.64

Other Income

0.54

0.77

0.57

Arvind Remedies Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,787.4

137.434,32,9601,181.050.755,985.3398.33

Divis Laboratories Ltd

DIVISLAB

6,012.5

79.591,65,003.325940.482,297513.62

Cipla Ltd

CIPLA

1,525.9

26.921,25,285.641,438.150.844,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,238.9

61.671,12,502.674850.842,330222.38

Mankind Pharma Ltd

MANKIND

2,557.5

55.531,07,385.94416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Arvind Remedies Ltd

Management

Register Office

Registrar Office

Managing Director & CEO

B Arvind Shah

Whole-time Director

Chandra Ravindran

Company Secretary

P R Krishnan

Director

Madhav Yadav

Additional Director

Timothy Allen

Additional Director

M Vasudevan

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Promoted by Arvind Kumar Shah, C M K Reddy, Chhotalal and Chandra Ravindran Arvind Remedies (ARL) was incorporated in Jun.88 as a private limited company which was later converted into a public limited company in Apr.95.ARL is engaged mainly formulation of Capsules and tablets. It manufactures over 80 products in various segments like ethical, generic and exports, besides institutions in the south. In 1999-2000, the company built up its own manufacturing facility at an expanded capacity of Tablets, Capsules, Liquids, Orals, Ointments, Ayurvedic preparations at Kakkalur, Thiruvallur Dist. under the state-of-the-art technology which is fully operational.In Nov.00, the company came out with a offering to existing shareholders through a rights issue of 14,86,000 equity shares of Rs 10 each at a premium of Rs 90 per share in the ratio of one equity share held for every four shares held.The company entered into an agreement into Bal Pharma Ltd Bangalore for manufacturing products of Bal Pharma Ltd. The company has decided to have a centralised distribution centre, for which it it going use already allotted 3 acres plot,which was allotted by SIDCO. The plans have been drawn to start the civil works and the proposed construction activities are scheduled to be completed in December,2002.
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.